Toronto Dominion Bank Buys Shares of 750,000 Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Toronto Dominion Bank purchased a new position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 750,000 shares of the company's stock, valued at approximately $1,770,000. Toronto Dominion Bank owned 1.41% of Milestone Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Jones Financial Companies Lllp boosted its stake in Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after acquiring an additional 10,000 shares during the last quarter. Virtu Financial LLC bought a new position in Milestone Pharmaceuticals during the 4th quarter worth approximately $170,000. National Bank of Canada FI boosted its stake in Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after acquiring an additional 11,600 shares during the last quarter. XTX Topco Ltd bought a new position in Milestone Pharmaceuticals during the 4th quarter worth approximately $80,000. Finally, Northern Trust Corp boosted its stake in Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after acquiring an additional 30,772 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company's stock.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock traded down $0.04 on Wednesday, hitting $1.65. The company's stock had a trading volume of 575,727 shares, compared to its average volume of 913,994. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. The stock's 50 day moving average is $1.14 and its 200-day moving average is $1.69. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $2.75. The company has a market capitalization of $88.22 million, a PE ratio of -2.04 and a beta of 0.92.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.12). Equities research analysts expect that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on MIST shares. TD Securities lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. TD Cowen lowered shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Cowen lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $17.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.